Drug Trial Radar · NCT00042289
Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
Last checked: Nov 19, 2026Latest source record: Dec 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,578
Actual
Start
Jun 9, 2003
Primary completion
Sep 30, 2020
Study completion Sep 30, 2020
Sponsor
- Sponsor type
- NIH
- Collaborators
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- First posted
- Aug 1, 2002
Design
- Study type
- Observational
- Who can join
- All sexes
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
IMPAACT P1026s is a Phase IV prospective clinical study to evaluate the pharmacokinetics (PKs) of antiretroviral (ARV) and tuberculosis (TB) medications in pregnant women and their infants. (Pharmacokinetics are the various interactions between a drug and the body.) This study also evaluated the PKs of certain ARVs in postpartum women before and after starting hormonal contraceptives. The PKs of these drugs were evaluated by measuring the amount of medicine present in blood and/or vaginal secretions.
Conditions
- HIV Infections
Interventions
atazanavir/cobicistatDrug
atazanavir/cobicistat 300/150 mg q.d.
darunavir/ritonavir dosage #1Drug
darunavir/ritonavir twice daily 600/100 mg b.i.d.
darunavir/ritonavir dosage #2Drug
darunavir/ritonavir twice daily 800/100 mg b.i.d.
darunavir/ritonavir dosage #3Drug
darunavir/ritonavir twice daily 900/100 mg b.i.d.
elvitegravir/cobicistatDrug
elvitegravir/cobicistat 150/150 mg q.d.
dolutegravirDrug
dolutegravir 50 mg q.d.
tenofovir alafenamide fumarate (TAF)Drug
TAF 25 mg q.d. without cobicistat or ritonavir boosting
TAF w/cobicistatDrug
TAF 10 mg q.d. with cobicistat
TAF w/cobicistat or ritonavirDrug
TAF 25 mg q.d. with cobicistat or ritonavir boosting
efavirenzDrug
efavirenz 600 mg q.d.
darunavir/cobicistatDrug
darunavir/cobicistat 800/150 mg q.d.
lopinavir/ritonavir dosage #1Drug
lopinavir/ritonavir 800/200mg b.i.d.
atazanavir/ritonavir/tenofovir dosage #1Drug
atazanavir/ritonavir/tenofovir 300/100/300mg q.d.
rifampicinDrug
rifampicin 8-12 mg/kg (max 600 mg) q.d.; 8-12 mg/kg (max 900 mg) t.i.w.
ethambutolDrug
ethambutol 15-20 mg/kg q.d., 25-35 mg/kg t.i.w.
isoniazidDrug
isoniazid 4-6 mg/kg (max 300 mg) q.d.; 8-12 mg/kg (max 900 mg) t.i.w.
pyrazinamideDrug
pyrazinamide 20-30mg/kg q.d.; 30-40mg/kg t.i.w.
kanamycinDrug
kanamycin (2nd line TB drug)
amikacinDrug
amikacin (2nd line TB drug)
capreomycinDrug
capreomycin (2nd line TB drug)
moxifloxacinDrug
moxifloxacin (2nd line TB drug)
levoflaxacinDrug
levofloxacin (2nd line TB drug)
ofloxacinDrug
ofloxacin (2nd line TB drug)
ethionamide/prothionamideDrug
ethionamide/prothionamide (2nd line TB drug)
terizidone/cycloserineDrug
terizidone/cycloserine (2nd line TB drug)
para-aminosalicylic acid (PAS)Drug
para-aminosalicylic acid (PAS) (2nd line TB drug)
high dose INHDrug
high dose INH (2nd line TB drug)
bedaquilineDrug
bedaquiline (2nd line TB drug)
clofazamineDrug
clofazamine (2nd TB drug)
delamanidDrug
delamanid (2nd line TB drug)
linezolidDrug
linezolid (2nd line TB drug)
pretomanidDrug
pretomanid (2nd line TB drug)
ethinyl estradiolDrug
oral contraceptives formulated with 30-35 μg ethinyl estradiol
etonogestrel implantDrug
etonogestrel implant contraceptive
nevirapineDrug
nevirapine 200 mg twice a day
amprenavirDrug
amprenavir 1200mg twice a day
abacavirDrug
abacavir 300mg twice a day
lopinavir/ritonavir dosage #2Drug
lopinavir/ritonavir (Kaletra) 400/100mg twice a day
indinavir/ritonavir dosage #1Drug
indinavir/ritonavir 800/100mg twice a day
fosamprenavir/ritonavirDrug
fosamprenavir/ritonavir 700/100 mg twice a day
lopinavir/ritonavir dosage #3Drug
lopinavir/ritonavir (Kaletra) 533/133 mg twice a day
atazanavir/ritonavir dosage #1Drug
atazanavir/ritonavir 300/100 mg once a day
didanosine delayed release (Videx® EC)Drug
didanosine delayed release (Videx® EC) 400 mg once a day if weight \> 60 kg; 250 mg once a day if weight \< 60 kg
emtricitabineDrug
emtricitabine 200 mg once a day
tenofovirDrug
tenofovir 300 mg once a day
nelfinavir dosage #1Drug
nelfinavir \[625 mg tablets\] 1250 mg twice a day
tipranavir/ritonavirDrug
tipranavir/ritonavir 500/200 mg twice a day
lopinavir/ritonavir dosage #4Drug
lopinavir/ritonavir (Kaletra) tablets 600/150 mg \[3 tablets\] twice a day
raltegravirDrug
raltegravir 400 mg twice a day
etravirineDrug
etravirine 200 mg twice a day
maravirocDrug
maraviroc 150 mg or 300 mg twice a day
atazanavir/ritonavir dosage #2Drug
atazanavir/ritonavir 400/100mg once a day
tenofovir/atazanavir/ritonavir dosage #2Drug
tenofovir/atazanavir/ritonavir 300/400/100 mg once a day
nelfinavir dosage #2Drug
nelfinavir \[625 mg tablets\] 1875 mg twice a day
indinavir/ritonavir dosage #2Drug
indinavir/ritonavir 400/100 mg twice a day
rilpivirineDrug
rilpivirine (25 mg q.d.)
darunavir/ritonavir dosage #4Drug
darunavir/ritonavir once daily 800/100 mg q.d.
Primary outcomes
What the sponsor says the trial is designed to measure.
- PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Median (IQR) for ARVs and TB DrugsTime frame: Measured in 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks, or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, and 12 hrs post dosing.
- PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Median (Range) for ARVs and TB DrugsTime frame: Measured in 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks, or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, and 12 hrs post dosing.
- PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Geometric Mean (95% CI) for ARVs and TB DrugsTime frame: Measured in 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks, or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, and 12 hrs post dosing.
- PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (IQR) for ARVs and TB DrugsTime frame: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, 12 and 24 hours post dosing.
- PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (Range) for ARVs and TB DrugsTime frame: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, 12 and 24 hours post dosing.
- PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (IQR) for ARVs and TB DrugsTime frame: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm; Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8,12 (and 24) hours post dosing.
- PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (Range) for ARVs and TB DrugsTime frame: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm; Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8,12 (and 24) hours post dosing.
- PK Parameter: Maximum Concentration (Cmax) in ng/mL With Median (IQR) for ARVs and TB DrugsTime frame: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm; Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8,12 (and 24) hours post dosing.
- PK Parameter: Maximum Concentration (Cmax) in ng/mL With Median (95% CI) for ARVs and TB DrugsTime frame: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm; Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8,12 (and 24) hours post dosing.
- PK Parameter: Trough Concentration (C12) With Median (IQR) for ARVs and TB DrugsTime frame: Measured at 2nd trimester (20-26 wks gestation); 3rd trimester (30-38 gestation); and either 2-3 wks, 2-8 wks, or 6-12 wks postpartum, depending on study arm. Trough concentration was measured 12 hrs after an observed dose.
- PK Parameter: Trough Concentration (C12) With Median (Range) for ARVs and TB DrugsTime frame: Measured at 2nd trimester (20-26 wks gestation); 3rd trimester (30-38 gestation); and either 2-3 wks, 2-8 wks, or 6-12 wks postpartum, depending on study arm. Trough concentration was measured 12 hrs after an observed dose.
- PK Parameter: Trough Concentration (C12) With Geometric Mean (95% CI) for ARVs and TB DrugsTime frame: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Trough concentration was measured 12 hrs after an observed dose.
- PK Parameter: Trough Concentration (C24) With Median (IQR) for ARVs and TB DrugsTime frame: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Trough concentration was measured 24 hrs after an observed dose.
- PK Parameter: Trough Concentration (C24) With Median (Range) for ARVs and TB DrugsTime frame: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Trough concentration was measured 24 hrs after an observed dose.
- Number of Women Who Met PK Target of Area Under the Curve (AUC) for ARVsTime frame: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, 12 (and 24) hours post dosing.
- Number of Women Who Met PK Target of Maximum Concentration (Cmax) for First Line TB DrugsTime frame: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, 12 (and 24) hours post dosing.
- Plasma Concentration for ContraceptivesTime frame: Measured at 6-7 weeks after contraceptive initiation postpartum
- Area Under the Curve From 0 to 12 Hours (AUC12) of ARVs for Contraceptive ArmsTime frame: Measured at 2-12 wks postpartum before contraceptive initiation and 6-7 wks after contraceptive initiation. Blood samples were drawn pre-dose and at 0, 1, 2, 6, 8 and 12 hours post dosing.
- Area Under the Curve From 0 to 24 Hours (AUC24) of ARVs for Contraceptive ArmsTime frame: Measured at 2-12 wks postpartum before contraceptive initiation and 6-7 wks after contraceptive initiation. Blood samples were drawn pre-dose and at 0, 1, 2, 6, 8, 12, and 24 hours post dosing.
Locations
62 sites in 8 countries. Site status is shown where the registry gives one.
UAB Pediatric Infectious Diseases CRS
Birmingham, Alabama
University of California, UC San Diego CRS- Mother-Child-Adolescent HIV Program
La Jolla, California
Miller Children's Hosp. Long Beach CA NICHD CRS
Long Beach, California
Usc La Nichd Crs
Los Angeles, California
David Geffen School of Medicine at UCLA NICHD CRS
Los Angeles, California
Univ. of California San Francisco NICHD CRS
San Francisco, California
Harbor UCLA Medical Ctr. NICHD CRS
Torrance, California
Univ. of Colorado Denver NICHD CRS
Aurora, Colorado
Yale Univ. School of Medicine - Dept. of Peds., Div. of Infectious Disease
New Haven, Connecticut
Washington Hosp. Ctr. NICHD CRS
Washington D.C., District of Columbia
Univ. of Florida Jacksonville NICHD CRS
Jacksonville, Florida
Pediatric Perinatal HIV Clinical Trials Unit CRS
Miami, Florida
USF - Tampa NICHD CRS
Tampa, Florida
Emory University School of Medicine NICHD CRS
Atlanta, Georgia
Med. College of Georgia School of Medicine, Dept. of Peds., Div. of Infectious Diseases
Augusta, Georgia
Mt. Sinai Hosp. Med. Ctr. - Chicago, Womens & Childrens HIV Program
Chicago, Illinois
Rush Univ. Cook County Hosp. Chicago NICHD CRS
Chicago, Illinois
Univ. of Illinois College of Medicine at Chicago, Dept. of Peds.
Chicago, Illinois
Lurie Children's Hospital of Chicago (LCH) CRS
Chicago, Illinois
Tulane Univ. New Orleans NICHD CRS
New Orleans, Louisiana
Univ. of Maryland Baltimore NICHD CRS
Baltimore, Maryland
Johns Hopkins Univ. Baltimore NICHD CRS
Baltimore, Maryland
Children's Hosp. of Boston NICHD CRS
Boston, Massachusetts
Boston Medical Center Ped. HIV Program NICHD CRS
Boston, Massachusetts
Baystate Health, Baystate Med. Ctr.
Springfield, Massachusetts
WNE Maternal Pediatric Adolescent AIDS CRS
Worcester, Massachusetts
Children's Hospital of Michigan NICHD CRS
Detroit, Michigan
Rutgers - New Jersey Medical School CRS
Newark, New Jersey
Nyu Ny Nichd Crs
New York, New York
Metropolitan Hosp. NICHD CRS
New York, New York
Columbia IMPAACT CRS
New York, New York
SUNY Stony Brook NICHD CRS
Stony Brook, New York
Bronx-Lebanon Hospital Center NICHD CRS
The Bronx, New York
Jacobi Med. Ctr. Bronx NICHD CRS
The Bronx, New York
DUMC Ped. CRS
Durham, North Carolina
Philadelphia IMPAACT Unit CRS
Philadelphia, Pennsylvania
Regional Med. Ctr. at Memphis
Memphis, Tennessee
St. Jude Children's Research Hospital CRS
Memphis, Tennessee
Seattle Children's Research Institute CRS
Seattle, Washington
Hosp. General de Agudos Buenos Aires Argentina NICHD CRS
Ciudad de Buenos Aires, Buenos Aires, Argentina
Showing 40 of 62 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.